{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alpha-1+15%25",
    "query": {
      "intervention": "Alpha-1 15%"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alpha-1+15%25&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T07:25:02.101Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01145183",
      "title": "Pharmacogenetics of Doxazosin for Cocaine Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cocaine Dependence"
      ],
      "interventions": [
        {
          "name": "Doxazosin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 96,
      "start_date": "2010-03",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2019-07-22",
      "last_synced_at": "2026-09-15T07:25:02.101Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01145183"
    },
    {
      "nct_id": "NCT01379469",
      "title": "Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha-1-antitrypsin Deficiency",
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Drug-Carbamazepine (Tegretol XR)",
          "type": "DRUG"
        },
        {
          "name": "Carbamazepine (Tegretol XR) Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "14 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2012-01",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-09-15T07:25:02.101Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01379469"
    },
    {
      "nct_id": "NCT04722887",
      "title": "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alpha1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Alpha-1 15%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Liquid Alpha1-Proteinase Inhibitor (Human)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 17,
      "start_date": "2021-08-13",
      "completion_date": "2025-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-12",
      "last_synced_at": "2026-09-15T07:25:02.101Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04722887"
    },
    {
      "nct_id": "NCT03221751",
      "title": "Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dementia"
      ],
      "interventions": [
        {
          "name": "prazosin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2016-12-01",
      "completion_date": "2023-12-05",
      "has_results": true,
      "last_update_posted_date": "2024-02-26",
      "last_synced_at": "2026-09-15T07:25:02.101Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03221751"
    },
    {
      "nct_id": "NCT00762710",
      "title": "Study of the Medication Prazosin for Alcohol Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcoholism"
      ],
      "interventions": [
        {
          "name": "Prazosin medication",
          "type": "DRUG"
        },
        {
          "name": "Placebo medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seattle Institute for Biomedical and Clinical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2008-01",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2020-06-04",
      "last_synced_at": "2026-09-15T07:25:02.101Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00762710"
    },
    {
      "nct_id": "NCT03972683",
      "title": "Role of Acetylcholine in Blood Flow Regulation in Healthy Adults: Effects of Age and Exercise Training",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Vasoconstriction",
        "Vasodilation"
      ],
      "interventions": [
        {
          "name": "Handgrip Exercise Training",
          "type": "OTHER"
        },
        {
          "name": "Acetylcholine",
          "type": "DRUG"
        },
        {
          "name": "Adenosine Triphosphate",
          "type": "DRUG"
        },
        {
          "name": "Atropine",
          "type": "DRUG"
        },
        {
          "name": "Phenylephrine",
          "type": "DRUG"
        },
        {
          "name": "Sodium Nitroprusside",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Colorado State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-04-16",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-08-02",
      "last_synced_at": "2026-09-15T07:25:02.101Z",
      "location_count": 1,
      "location_summary": "Fort Collins, Colorado",
      "locations": [
        {
          "city": "Fort Collins",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03972683"
    },
    {
      "nct_id": "NCT07555483",
      "title": "A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alpha 1 Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Alpha-1 15%",
          "type": "DRUG"
        },
        {
          "name": "Liquid Alpha1-PI",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2026-05-05",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-15T07:25:02.101Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angelas",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07555483"
    },
    {
      "nct_id": "NCT01703559",
      "title": "The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Night Vision Complaints",
        "Decrease in Night Vision",
        "Disturbance; Vision, Loss"
      ],
      "interventions": [
        {
          "name": "Phentolamine Mesylate Ophthalmic Solution 1.0%",
          "type": "DRUG"
        },
        {
          "name": "Phentolamine Mesylate Ophthalmic Solution 0.5%",
          "type": "DRUG"
        },
        {
          "name": "Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ocuphire Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 60,
      "start_date": "2011-09-09",
      "completion_date": "2012-04-30",
      "has_results": false,
      "last_update_posted_date": "2019-08-01",
      "last_synced_at": "2026-09-15T07:25:02.101Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01703559"
    },
    {
      "nct_id": "NCT01523821",
      "title": "Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Graft-Versus-Host Disease (GVHD) Acute on Chronic"
      ],
      "interventions": [
        {
          "name": "Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2013-10-11",
      "completion_date": "2017-01-15",
      "has_results": true,
      "last_update_posted_date": "2018-10-30",
      "last_synced_at": "2026-09-15T07:25:02.101Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01523821"
    },
    {
      "nct_id": "NCT01953432",
      "title": "Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cocaine Dependence"
      ],
      "interventions": [
        {
          "name": "Doxazosin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 43,
      "start_date": "2014-04-01",
      "completion_date": "2017-10-01",
      "has_results": true,
      "last_update_posted_date": "2020-02-20",
      "last_synced_at": "2026-09-15T07:25:02.101Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01953432"
    }
  ]
}